A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

The pulmonary arterial hypertension (PAH) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK ...

Austria’s HeartBeat.bio and biotx.ai have announced a strategic partnership to identify and validate novel therapeutic ...

Swissmedic has introduced a fast-track review process for clinical trial applications, aiming to speed up access to ...

Last week’s announcement of a Life Science Strategy from the European Commission, includes action to address long-standing ...

Since July 2016, and in line with the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the ...

A Dutch appeals court has ruled that health insurers acted unlawfully in their group tender for three CDK 4/6 inhibitors, ...

US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate ...

An Expert View from Justin Kozak, life sciences industry lead, Founder Shield.

The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA), through the Executive Steering Group on ...

Theratechnologies, a Canada-based biopharma, is to be acquired by CB Biotechnology, an affiliate of Future Pak, a ...

Spanish gene therapy specialist VIVEbiotech has named Patricio Massera as its new president, bringing in a seasoned CDMO ...